Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 9/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | POLQ | O75417 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3535171 | 0.83 | PIK3CA (0.61) | PIK3CAPIK3CDFGFR4EGFRTDO2 | |
| SCHEMBL29804751 | 0.81 | PIK3CA (0.54) | PIK3CAPIK3CDFGFR4EGFRTDO2 | |
| SCHEMBL29985188 | 0.79 | EGFR (0.60) | PIK3CAPIK3CDFGFR4EGFRTDO2 | |
| SCHEMBL1771905 | 0.79 | EGFR (0.60) | PIK3CAPIK3CDFGFR4EGFRTDO2 | |
| SCHEMBL8644295 | 0.79 | PIK3CA (0.73) | PIK3CAPIK3CDFGFR4EGFRTDO2 | |
| SCHEMBL12386956 | 0.78 | ALDH1A1 (0.62) | CCR1CCR5CCR8HDAC6CYP3A4 | |
| SCHEMBL28801910 | 0.78 | EGFR (0.58) | PIK3CAPIK3CDFGFR4EGFRTDO2 | |
| SCHEMBL20929593 | 0.76 | CCR1 (0.56) | CCR1CCR5CCR8HDAC6CYP3A4 | |
| SCHEMBL12386961 | 0.76 | CYP3A4 (0.54) | PIK3CAPIK3CDTDO2CCR1CCR5 | |
| SCHEMBL12386963 | 0.76 | CYP3A4 (0.54) | PIK3CAPIK3CDEGFRTDO2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466820-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-11 | — | — | US | disclosed |
| US-20220227749-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHARLES RIVER LABORATORIES, INC. | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227749-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | PIK3CA 627/4885PIK3CD 521/4885FGFR4 1926/4885 |
| US-12466820-B2 | Amino quinazoline derivatives as P2X3 inhibitors | P2RX3, P2RX5, P2RX1 | PIK3CA 627/4885PIK3CD 521/4885FGFR4 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.